Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Gross Margin (2018 - 2025)

UroGen Pharma (URGN) has disclosed Gross Margin for 8 consecutive years, with 91.31% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 137.0% year-over-year to 91.31%, compared with a TTM value of 88.66% through Dec 2025, down 151.0%, and an annual FY2025 reading of 88.66%, down 151.0% over the prior year.
  • Gross Margin was 91.31% for Q4 2025 at UroGen Pharma, up from 88.07% in the prior quarter.
  • Across five years, Gross Margin topped out at 91.31% in Q4 2025 and bottomed at 85.34% in Q2 2025.
  • Average Gross Margin over 5 years is 88.85%, with a median of 88.82% recorded in 2022.
  • The sharpest move saw Gross Margin soared 397bps in 2024, then plummeted -446bps in 2025.
  • Year by year, Gross Margin stood at 90.18% in 2021, then decreased by -3bps to 87.49% in 2022, then rose by 3bps to 90.28% in 2023, then decreased by 0bps to 89.94% in 2024, then rose by 2bps to 91.31% in 2025.
  • Business Quant data shows Gross Margin for URGN at 91.31% in Q4 2025, 88.07% in Q3 2025, and 85.34% in Q2 2025.